Accession Number:

AD1093126

Title:

Could HER2 Heterogeneity Open New Therapeutic Options in Patients with HER2-Primary Breast Cancer

Descriptive Note:

Technical Report,30 Sep 2017,29 Sep 2018

Corporate Author:

Memorial Sloan Kettering Cancer Center New York United States

Personal Author(s):

Report Date:

2018-10-01

Pagination or Media Count:

43.0

Abstract:

The purpose of this study is to determine if targeted imaging with a HER2-targeting PET tracer can detect HER2-positive metastases inpatients with HER2-negative primary breast cancer. 43 of a potential 50 patients have been accrued to the trial. The first phase of the trial composed of 23 patients with HER2-negative primary breast cancer who were imaged with 89Zr-trastuzumab PETCT. In 3 of these 23 patients, 89Zr-trastuzumab showed biopsy-proven HER2-positive metastases in patients with presumed HER2-negative primary disease, demonstrating the proof-of-concept that targeted imaging may help identify patients eligible for targeted therapies. However, in 6additional patients, 89Zr-trastuzumab-avid foci were HER2-negative on pathology, and these false-positives limit the utility of 89Zrtrastuzumab imaging. A more specific radiotracer was needed. The second phase of the trial was first-in-human 89Zr-pertuzumab PETCT, as a potentially more specific radiotracer. Six patients with HER2-positive metastatic breast cancer were imaged with 89Zrpertuzumab PETCT, demonstrating safety, dosimetry, and effectiveness of 89Zr-pertuzumab to image HER2-positive disease. The third phase of the trial is 89Zr-pertuzumab PETCT in patients with HER2-negative primary breast cancer, to identify unsuspected HER2-positive metastases. 14 patients have been accrued, with one patient demonstrating HER2-positive metastases. Three manuscripts have been published on this work PMID 29146695, 28872549, 27151988, and a final manuscript will be prepared at its conclusion.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE